These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 36366476)

  • 1. On the Need to Determine the Contribution of Anti-Nucleocapsid Antibodies as Potential Contributors to COVID-19 Convalescent Plasma Efficacy.
    Focosi D; Franchini M; Casadevall A
    Viruses; 2022 Oct; 14(11):. PubMed ID: 36366476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nucleocapsid-specific antibody function is associated with therapeutic benefits from COVID-19 convalescent plasma therapy.
    Herman JD; Wang C; Burke JS; Zur Y; Compere H; Kang J; Macvicar R; Taylor S; Shin S; Frank I; Siegel D; Tebas P; Choi GH; Shaw PA; Yoon H; Pirofski LA; Julg BD; Bar KJ; Lauffenburger D; Alter G
    Cell Rep Med; 2022 Nov; 3(11):100811. PubMed ID: 36351430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early Treatment with Monoclonal Antibodies or Convalescent Plasma Reduces Mortality in Non-Vaccinated COVID-19 High-Risk Patients.
    Thümmler L; Lindemann M; Horn PA; Lenz V; Konik M; Gäckler A; Boss K; Theodoropoulos F; Besa V; Taube C; Brenner T; Witzke O; Krawczyk A; Rohn H
    Viruses; 2022 Dec; 15(1):. PubMed ID: 36680159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody Response against SARS-CoV-2 Infection: Implications for Diagnosis, Treatment and Vaccine Development.
    Mallano A; Ascione A; Flego M
    Int Rev Immunol; 2022; 41(4):393-413. PubMed ID: 34494500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential use of convalescent plasma for SARS-CoV-2 prophylaxis and treatment in immunocompromised and vulnerable populations.
    Focosi D; Franchini M
    Expert Rev Vaccines; 2022 Jul; 21(7):877-884. PubMed ID: 34015243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic potential of convalescent plasma and hyperimmune immunoglobulins against SARS-CoV-2 BQ.1, BQ.1.1, and XBB variants.
    Bellusci L; Golding H; Khurana S
    J Clin Invest; 2023 Apr; 133(8):. PubMed ID: 36821375
    [No Abstract]   [Full Text] [Related]  

  • 7. COVID-19 Convalescent Plasma Is More than Neutralizing Antibodies: A Narrative Review of Potential Beneficial and Detrimental Co-Factors.
    Focosi D; Franchini M; Pirofski LA; Burnouf T; Fairweather D; Joyner MJ; Casadevall A
    Viruses; 2021 Aug; 13(8):. PubMed ID: 34452459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Respiratory delivery of passive immunotherapies for SARS-CoV-2 prophylaxis and therapy.
    Focosi D; Maggi F
    Hum Vaccin Immunother; 2023 Aug; 19(2):2260040. PubMed ID: 37799070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibodies, epicenter of SARS-CoV-2 immunology.
    Pecetta S; Pizza M; Sala C; Andreano E; Pileri P; Troisi M; Pantano E; Manganaro N; Rappuoli R
    Cell Death Differ; 2021 Feb; 28(2):821-824. PubMed ID: 33500559
    [No Abstract]   [Full Text] [Related]  

  • 10. Development and application of therapeutic antibodies against COVID-19.
    Ning L; Abagna HB; Jiang Q; Liu S; Huang J
    Int J Biol Sci; 2021; 17(6):1486-1496. PubMed ID: 33907512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Convalescent Plasma Therapy in Immunocompromised Patients Infected With the BA.1 or BA.2 Omicron SARS-CoV-2.
    Richier Q; De Valence B; Chopin D; Gras E; Levi LI; Abi Aad Y; Pacanowski J; Meynard JL; Plaçais L; Fey D; Couture P; Martin-Blondel G; Pestre V; Woessner J; Ancellin S; Weyrich P; Carpentier B; Idri S; Tiberghien P; Surgers L; Hueso T; Lacombe K
    Influenza Other Respir Viruses; 2024 Mar; 18(3):e13272. PubMed ID: 38501337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of convalescent plasma for COVID-19 in India: A review & practical guidelines.
    Khaire NS; Jindal N; Yaddanapudi LN; Sachdev S; Hans R; Sachdeva N; Singh MP; Agarwal A; Mukherjee A; Kumar G; Sharma RR; Suri V; Puri GD; Malhotra P
    Indian J Med Res; 2021 Jan & Feb; 153(1 & 2):64-85. PubMed ID: 33818467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutralization capacity of convalescent plasma against SARS-CoV-2 omicron sublineages: Implications for donor selection.
    McGregor R; Carlton L; Paterson A; Hills T; Charlewood R; Moreland NJ
    Vox Sang; 2023 Dec; 118(12):1145-1147. PubMed ID: 37817295
    [No Abstract]   [Full Text] [Related]  

  • 14. Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline.
    Tuccori M; Ferraro S; Convertino I; Cappello E; Valdiserra G; Blandizzi C; Maggi F; Focosi D
    MAbs; 2020; 12(1):1854149. PubMed ID: 33319649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of convalescent plasma for pediatric patients with SARS-CoV-2: A systematic literature review.
    Zaffanello M; Piacentini G; Nosetti L; Franchini M
    Transfus Apher Sci; 2021 Apr; 60(2):103043. PubMed ID: 33388249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of combined COVID-19 convalescent plasma with oral RNA-dependent RNA polymerase inhibitor treatment versus neutralizing monoclonal antibody therapy in COVID-19 outpatients: a multi-center, non-inferiority, open-label randomized controlled trial (PlasMab).
    Siripongboonsitti T; Nontawong N; Tawinprai K; Suptawiwat O; Soonklang K; Poovorawan Y; Mahanonda N
    Microbiol Spectr; 2023 Dec; 11(6):e0325723. PubMed ID: 37975699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perspective on the Role of Antibodies and Potential Therapeutic Drugs to Combat COVID-19.
    Tandon S; Aggarwal A; Jain S; Shukla S; Chaudhary S
    Protein J; 2020 Dec; 39(6):631-643. PubMed ID: 33034824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fc-mediated functions and the treatment of severe respiratory viral infections with passive immunotherapy - a balancing act.
    Vanderven HA; Kent SJ
    Front Immunol; 2023; 14():1307398. PubMed ID: 38077353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COVID-19 therapy with mesenchymal stromal cells (MSC) and convalescent plasma must consider exosome involvement: Do the exosomes in convalescent plasma antagonize the weak immune antibodies?
    Askenase PW
    J Extracell Vesicles; 2020 Oct; 10(1):e12004. PubMed ID: 33304473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Late Administration and Corticosteroid Usage Explain Inefficacy in COVID-19 Convalescent Plasma Trial.
    Casadevall A; Sullivan DJ
    J Infect Dis; 2024 Feb; 229(2):617-618. PubMed ID: 37967364
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.